Biomarker Analysis in a Phase II Study of Sunitinib in Patients with Advanced Melanoma
(2015) Anticancer Research : international journal of cancer research and treatment — Vol. 35, n° 12, p. 6893-6899 (2015)
Files
No attached file found for this publication.
Details
- Authors
- Abstract
- AIM: To investigate the efficacy of sunitinib in patients with advanced melanoma and to correlate angiogenic biomarkers with response and survival. PATIENTS AND METHODS: We performed a phase II study in patients with advanced pre-treated melanoma. The primary endpoint was tumor response. Blood samples for biomarker analysis including vascular endothelial growth factor (VEGF), and its receptors VEGFR1 and -2, placental growth factor (PlGF) and circulating endothelial cells (CEC) were collected at baseline and during the first cycle. RESULTS: Four out of 39 patients (13%) achieved a partial response and eight (26%) stable disease. Time to progression was at least six months in seven patients. High baseline VEGFR1 levels and high baseline PlGF levels were both associated with a non-significant worse survival (p=0.08 for both). CONCLUSION: Sunitinib demonstrates limited activity in unselected patients with refractory advanced melanoma, but a minority of patients experienced long-term disease control. Identification of these patients remains a challenge.
- Affiliations
Citations
Decoster, L., Vande Broek, I., Neyns, B., Majois, F., Baurain, J.-F., Rottey, S., Rorive, A., Anckaert, E., De Mey, J., De Brakeleer, S., & De Grève, J. (2015). Biomarker Analysis in a Phase II Study of Sunitinib in Patients with Advanced Melanoma. Anticancer Research : international journal of cancer research and treatment, 35(12), 6893-6899. https://hdl.handle.net/2078.5/72502 (Original work published 2015)